INDOCO REMEDIES
|
|
| BOM : 532612     NSE : INDOCO     | |
| LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Average |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Oct 30,2025 |
|
Price(EOD): ₹ 280.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 2,583.44 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| INDOCO REMEDIES | -2.4% | -3.4% | -13.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.6% | 8.2% | -8.8% |
| DIVIS LABORATORIES | -0.8% | 14.4% | 12.2% |
| CIPLA | -3.9% | 5.5% | 5.2% |
| TORRENT PHARMACEUTICALS | -0.5% | 1% | 7.9% |
| DR REDDYS LABORATORIES | -2.1% | -0% | -2% |
| MANKIND PHARMA | -0.2% | -1.5% | -4.1% |
| ZYDUS LIFESCIENCES | -0.6% | 2.6% | -0.4% |
| LUPIN | 0.9% | 1.9% | -9.8% |
FUNDAMENTAL ANALYSIS OF INDOCO REMEDIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF INDOCO REMEDIES
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
-22.26
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -116.10 Cr
[Latest Qtr - Jun2025 - Consolidated Results ] 2.54
P/B Calculated based on Book Value of Rs 1,016.26 Cr
[Latest Year - Mar2025 - Consolidated Results ] 1.55
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,671.31 Cr
[Latest Qtr - Jun2025 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
2% -11% -15% |
SHARE PRICE MOMENTUM OF INDOCO REMEDIES
INDOCO REMEDIES vs SENSEX
DEBT OF INDOCO REMEDIES
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
0.67 0.44 0.31 0.47 |
0.96 0.59 0.31 0.62 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF INDOCO REMEDIES
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Sep2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF INDOCO REMEDIES
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
12.22% 2347.44% 19.46% 12.07% |
1.48% -63.3% -625.97% -2097.25% |
| QtrlyTrend |
2 | |
| Latest Qtr: Jun2025 | ||
| Quarterly Result Analysis → | ||
INDOCO REMEDIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE SMALLCAP | 0.9% | 3.5% | 0.8% |
| BSE HEALTHCARE | -0.8% | 4.2% | 4.6% |
You may also like the below Video Courses
FAQ about INDOCO REMEDIES
Is INDOCO REMEDIES good for long term investment?
As on Oct 30,2025, the Fundamentals of INDOCO REMEDIES look Strong and hence it may be good for long term investment! See Financial Performance of INDOCO REMEDIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is INDOCO REMEDIES UnderValued or OverValued?
As on Oct 30,2025, INDOCO REMEDIES is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of INDOCO REMEDIES ?
As on Oct 30,2025, the Intrinsic Value of INDOCO REMEDIES is Rs. 314.61 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 275.85
Fair Value [Median EV / Sales Model] : Rs. 314.61
Fair Value [Median Price / Sales Model] : Rs. 331.05
Estimated Median Fair Value of INDOCO REMEDIES : Rs. 314.61
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.